Spinal Cord

The FDA has approved an expanded indication of Boston Scientific’s spinal cord stimulation system that treats painful diabetic peripheral neuropathy, a complication of diabetes that often affects the lower extremities.

Horizon Therapeutics announced positive results of MRI data from the phase 3 clinical trial of Uplizna, which showed reduction in formation of subclinical transverse myelitis lesions in patients with neuromyelitis optica spectrum disorder.

Abbott has announced the FDA expanded the indication of its BurstDR spinal cord stimulation devices for treating chronic back pain in those who have not had or are ineligible for back surgery.

The FDA has approved expanded MRI labeling for Abbott’s Eterna spinal cord stimulation system, allowing those with chronic pain to undergo MRI within specific conditions and have a wider selection of lead options for full-body scans.

The FDA has approved Prospera, a spinal cord stimulation system to treat those with chronic intractable pain in the upper body and limbs.

The FDA has approved the Proclaim XR spinal cord stimulation system to treat painful diabetic peripheral neuropathy, manufacturer Abbott announced in a press release.

The FDA has granted premarket approval for Abbott’s Proclaim Plus spinal cord stimulation system, which can treat chronic pain across up to six areas of the body and is programmable to adjust to a person’s needs, the company announced in a release.

WEST PALM BEACH, Fla. — Spinal cord atrophy appeared to predict silent progression in relapse-onset MS, according to results of a single-center observational study presented at ACTRIMS Forum.

An implanted 10 kHz spinal cord stimulator combined with conventional care provides better pain relief and neurologic improvement for people with painful diabetic neuropathy compared with conventional care alone, according to a speaker.